Nucleic Acid Test for Epstein-Barr Virus

A new nucleic acid test (NAT) has been designed for the detection and quantification of the Epstein-Barr virus (EBV). The assay has received the CE Mark.

Called ReSSQ EBV assay, the test was developed by LightUp Technologies AB (Huddinge, Sweden). The test enables simpler and more accurate identification and quantification of disease-generating organisms. The unique LightUp probe at the heart of the method is designed to work with real-time polymerase chain reaction (PCR) and can be used in many medical applications. The assay is currently validated for use in conjunction with the LightCycler and ABI Prism 7000 SDS real-time PCR instruments.

Pursuant to a distribution agreement in June 2004 between LightUp Technologies and DakoCytomation (Glostrup, Denmark), the assay will be marketed and sold in Europe by DakoCytomation. Later, the assay will be made available throughout the world.

"We are happy to make this product available to clinicians and clinical laboratories involved in the management of immunocompromised patients,” commented Geoff Gower, director of microbiology at DakoCytomation. "EBV infection is, for example, a major risk factor for developing lymphoproliferative disease (PTLD), a life-threatening complication of organ transplantation.”




Related Links:
LightUp Technologies
DakoCytomation